Diffuse Optical Spectroscopy Imaging in Monitoring and Predicting Response in Patients With Locally Advanced Breast Cancer Undergoing Chemotherapy Before Surgery
Status: | Unknown status |
---|---|
Conditions: | Breast Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 10/14/2017 |
Start Date: | March 2011 |
Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging (DOSI)
RATIONALE: New imaging procedures, such as diffuse optical spectroscopy imaging, may help
measure a patient's response and allow doctors to plan better treatment.
PURPOSE: This clinical trial studies diffuse optical spectroscopy imaging in monitoring and
predicting response in patients with locally advanced breast cancer undergoing chemotherapy
before surgery.
measure a patient's response and allow doctors to plan better treatment.
PURPOSE: This clinical trial studies diffuse optical spectroscopy imaging in monitoring and
predicting response in patients with locally advanced breast cancer undergoing chemotherapy
before surgery.
OBJECTIVES:
Primary
- To determine whether the percentage change in the diffuse optical spectroscopy imaging
(DOSI) measurement of the tumor/normal (T/N) tissue optical index (TOI) from baseline to
mid-therapy is predictive of the final pathologic response of the primary tumor in
patients with locally advanced breast cancer treated with neoadjuvant chemotherapy.
Secondary
- To investigate whether change of TOI measurements from baseline to post-therapy are
predictive of the final pathologic response in these patients treated with this regimen.
- To investigate whether baseline TOI measurements are associated with final pathologic
response in patients treated with this regimen.
- To investigate whether TOI measurements at baseline, change from baseline to
mid-therapy, and change from baseline to post-therapy correlate with available MRI
volumetric imaging measurements.
- To investigate whether changes on TOI measurements from baseline to mid-therapy, and
from baseline to post-therapy, correlate with other standard-of-care imaging and/or any
MRI-imaging measurements.
- To explore whether additional optical endpoints and indices obtained during DOSI
measurements can be used to predict final pathologic response in patients treated with
this regimen.
- To determine a cutpoint for the percent change of TOI from baseline to mid-therapy that
is predictive of pathological complete response in patients treated with this regimen.
OUTLINE: This is a multicenter study.
Patients undergo diffuse optical spectroscopy imaging (DOSI) at baseline, 5-10 days after
initiation of neoadjuvant chemotherapy, during early- and mid-neoadjuvant therapy, and within
21 days after completion of neoadjuvant therapy. Results are compared to standard-of-care
imaging (e.g., MRI, ultrasound, mammography). Patients then undergo surgery.
Primary
- To determine whether the percentage change in the diffuse optical spectroscopy imaging
(DOSI) measurement of the tumor/normal (T/N) tissue optical index (TOI) from baseline to
mid-therapy is predictive of the final pathologic response of the primary tumor in
patients with locally advanced breast cancer treated with neoadjuvant chemotherapy.
Secondary
- To investigate whether change of TOI measurements from baseline to post-therapy are
predictive of the final pathologic response in these patients treated with this regimen.
- To investigate whether baseline TOI measurements are associated with final pathologic
response in patients treated with this regimen.
- To investigate whether TOI measurements at baseline, change from baseline to
mid-therapy, and change from baseline to post-therapy correlate with available MRI
volumetric imaging measurements.
- To investigate whether changes on TOI measurements from baseline to mid-therapy, and
from baseline to post-therapy, correlate with other standard-of-care imaging and/or any
MRI-imaging measurements.
- To explore whether additional optical endpoints and indices obtained during DOSI
measurements can be used to predict final pathologic response in patients treated with
this regimen.
- To determine a cutpoint for the percent change of TOI from baseline to mid-therapy that
is predictive of pathological complete response in patients treated with this regimen.
OUTLINE: This is a multicenter study.
Patients undergo diffuse optical spectroscopy imaging (DOSI) at baseline, 5-10 days after
initiation of neoadjuvant chemotherapy, during early- and mid-neoadjuvant therapy, and within
21 days after completion of neoadjuvant therapy. Results are compared to standard-of-care
imaging (e.g., MRI, ultrasound, mammography). Patients then undergo surgery.
DISEASE CHARACTERISTICS:
- Diagnosis of invasive breast cancer by clinical breast examination, by standard of
care diagnostic imaging, or by initial tissue biopsy (confirmed by the local site
pathologist)
- Locally advanced disease
- Planned primary systemic (neoadjuvant) chemotherapy and surgical resection of residual
primary tumor (mastectomy or lumpectomy/breast conservation) following completion of
neoadjuvant chemotherapy
- No contraindications for primary chemotherapy
- Tumor size ≥ 2 cm by imaging or estimated by physical exam
- Hormone receptor status not specified
PATIENT CHARACTERISTICS:
- Menopausal status not specified
- ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%
- WBC ≥ 3,000/μL
- ANC ≥ 1,500/μL
- Platelet count ≥ 100,000/μL
- Total bilirubin normal
- AST and ALT ≤ 2.5 times upper limit of normal (ULN)
- Creatinine normal OR creatinine clearance ≥ 30 mL/min
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No uncontrolled intercurrent illness including, but not limited to, any of the
following:
- Ongoing or active infection
- Symptomatic congestive heart failure
- Unstable angina pectoris
- Cardiac arrhythmia
- Psychiatric illness and/or social situations that would limit compliance with
study requirements
- Not medically unstable
- At least 5 years since prior malignancy except basal cell or squamous cell carcinoma
of the skin, or in situ carcinoma of the cervix
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No prior chemotherapy, radiotherapy, or surgery to involved breast, including hormone
therapy
We found this trial at
2
sites
One Medical Center Drive
Lebanon, New Hampshire 03756
Lebanon, New Hampshire 03756
(603) 653-9000
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center Norris Cotton Cancer Center at DHMC in...
Click here to add this to my saved trials
101 The City Drive South
Irvine, California 92617
Irvine, California 92617
Click here to add this to my saved trials